pemetrexed koanaa pdr/conc/soln for infus 100mg
koanaa healthcare gmbh fehrgasse 7, 2401, fischamend,, austria - pemetrexed - concentrate for solution for infusion - pemetrexed 100 mg - antineoplastic agents
pemetrexed koanaa pdr/conc/soln for infus 500mg
koanaa healthcare gmbh fehrgasse 7, 2401, fischamend,, austria - pemetrexed - powder for concentrate for solution for infusion - pemetrexed 500 mg - antineoplastic agents
pemetrexed ever pharma 25 mg/ml concentrate for solution for infusion
ever valinject gmbh - pemetrexed - concentrate for solution for infusion - 25 milligram(s)/millilitre - pemetrexed
pemetrexed sun pemetrexed (as disodium) 1000mg/vial powder for injection vial
sun pharma anz pty ltd - pemetrexed disodium, quantity: 1102.8 mg (equivalent: pemetrexed, qty 1000 mg) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; hydrochloric acid - malignant pleural mesothelioma pemetrexed sun, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer pemetrexed sun in combination with cisplatin is indicated for initial treatment of patients with locally advance or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed sun as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.
pemetrexed sun pemetrexed (as disodium) 500mg/vial powder for injection vial
sun pharma anz pty ltd - pemetrexed disodium, quantity: 551.4 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; hydrochloric acid - malignant pleural mesothelioma pemetrexed sun, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer pemetrexed sun in combination with cisplatin is indicated for initial treatment of patients with locally advance or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed sun as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.
pemetrexed sun pemetrexed (as disodium) 100mg/vial powder for injection vial
sun pharma anz pty ltd - pemetrexed disodium, quantity: 110.28 mg (equivalent: pemetrexed, qty 100 mg) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; hydrochloric acid - malignant pleural mesothelioma pemetrexed sun, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer pemetrexed sun in combination with cisplatin is indicated for initial treatment of patients with locally advance or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed sun as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.
pemetrexed apotex pemetrexed 500 mg (as disodium) powder for injection vial
arrotex pharmaceuticals pty ltd - pemetrexed disodium hemipentahydrate, quantity: 604 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: mannitol; hydrochloric acid; sodium hydroxide - malignant pleural mesothelioma,pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer (nsclc),pemetrexed, in combination with cisplatin, is indicated for initial treatment of patients with locally advanced or metastatic nsclc other than predominantly squamous cell histology.,pemetrexed, as monotherapy, is indicated for the treatment of patients with locally advanced or metastatic nsclc other than predominantly squamous cell histology after prior platinum-based chemotherapy.
pemetrexed actavis pdr/conc/soln for infus 100mg
actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - pemetrexed - powder for concentrate for solution for infusion - pemetrexed 100 mg - antineoplastic agents
pemetrexed actavis pdr/conc/soln for infus 500mg
actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - pemetrexed - powder for concentrate for solution for infusion - pemetrexed 500 mg - antineoplastic agents
pemetrexed-teva pemetrexed (as disodium) 500mg powder for injection vial
teva pharma australia pty ltd - pemetrexed, quantity: 500 mg - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; hydrochloric acid; nitrogen - malignant pleural mesothelioma pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma. non-small cell lung cancer pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.